<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MONTELUKAST SODIUMÂ - montelukast sodiumÂ tablet, film coatedÂ </strong><br><strong>MONTELUKAST SODIUMÂ - montelukast sodiumÂ tablet, chewableÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use montelukast sodium safely and effectively.  See full prescribing information for montelukast sodium.<br>MONTELUKAST SODIUM tablets and chewable tablets for oral use <br>Initial U.S. Approval: 1998</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Montelukast sodium is a leukotriene receptor antagonist indicated for: </p>
<ul>
<li>Prophylaxis and chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in patients 12 months of age and older (<a href="#i4i_section_id_28894606-e746-4382-a678-5aa3b31b7edc">1.1</a>).</li>
<li>Acute prevention of exercise-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> (EIB) in patients 15 years of age and older (<a href="#i4i_section_id_7ba0e1d5-0bef-4262-86fa-9398cf6026fe">1.2</a>).</li>
<li>Relief of symptoms of <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> (AR): <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> (SAR) in patients 2 years of age and older, and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> (PAR) in patients 6 months of age and older (<a href="#i4i_section_id_82879b0a-3bef-48c8-bdef-e720d270f03e">1.3</a>).</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Administration (by indications): </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> (<a href="#i4i_section_id_03ab470c-0533-49ef-88da-18f7ffea21f5">2.1</a>): Once daily in the evening for patients 12 months and older.</li>
<li>Acute prevention of EIB (<a href="#i4i_section_id_5eec40d0-9b4f-477f-b7bc-459431c3ea2e">2.2</a>): 10 mg tablet at least 2 hours before exercise for patients 15 years of age and older.</li>
<li><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal allergic rhinitis</span> (<a href="#i4i_section_id_2670796a-9627-43c9-9d39-f54f0e505953">2.3</a>): Once daily for patients 2 years and older.</li>
<li><span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial allergic rhinitis</span> (<a href="#i4i_section_id_2670796a-9627-43c9-9d39-f54f0e505953">2.3</a>): Once daily for patients 6 months and older.</li>
</ul>
<p class="Highlighta">Dosage (by age) (<a href="#i4i_dosage_admin_id_4f311a68-e4df-43bb-b7fa-d35c9fe4d0a2">2</a>): </p>
<ul>
<li>15 years and older: one 10 mg tablet.</li>
<li>6 to 14 years: one 5 mg chewable tablet.</li>
<li>2 to 5 years: one 4 mg chewable tablet.</li>
</ul>
<p class="Highlighta">Patients with both <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> should take only one dose daily in the evening (<a href="#i4i_section_id_e584c492-5623-4e7a-b443-6e30e6c29a3c">2.4</a>). </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>Montelukast sodium film-coated tablets, 10 mg (montelukast)</li>
<li>Montelukast sodium chewable tablets, 4 mg (montelukast) and 5 mg (montelukast)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product (<a href="#i4i_contraindications_id_303a87a6-1288-437a-82ed-31c20a25ad3a">4</a>).</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Do not prescribe montelukast sodium to treat an acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack (<a href="#i4i_section_id_cc82beeb-2c9e-4711-b41b-9b689d2c0e98">5.1</a>).</li>
<li>Advise patients to have appropriate rescue medication available (<a href="#i4i_section_id_cc82beeb-2c9e-4711-b41b-9b689d2c0e98">5.1</a>).</li>
<li>Inhaled corticosteroid may be reduced gradually. Do not abruptly substitute montelukast sodium for inhaled or oral corticosteroids (<a href="#i4i_section_id_8066a099-cd3a-402d-89c0-4aa47f774102">5.2</a>).</li>
<li>Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium (<a href="#i4i_section_id_513ae70f-5548-4576-b537-256c272abe2e">5.3</a>).</li>
<li>Neuropsychiatric events have been reported with montelukast sodium. Instruct patients to be alert for neuropsychiatric events. Evaluate the risks and benefits of continuing treatment with montelukast sodium if such events occur (<a href="#i4i_section_id_bda8d701-d5f1-4df4-9fbf-4482043a56a9">5.4</a> and <a href="#i4i_section_id_75766023-8edf-4555-8d0a-93d8264d5994">6.2</a>).</li>
<li>Systemic <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, sometimes presenting with clinical features of <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> consistent with Churg-Strauss syndrome, has been reported. These events usually, but not always, have been associated with the reduction of oral corticosteroid therapy (<a href="#i4i_section_id_0710497a-3f35-41c7-b6b6-ec0f0e50dfad">5.5</a> and <a href="#i4i_section_id_75766023-8edf-4555-8d0a-93d8264d5994">6.2</a>).</li>
<li>Inform patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">phenylketonuria</span> that the 4 mg and 5 mg chewable tablets contain phenylalanine (<a href="#i4i_section_id_e5bd430c-d98c-44d5-8d23-9777274e7a08">5.6</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence â‰¥ 5% and greater than placebo listed in descending order of frequency): <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span> (<a href="#i4i_section_id_b47b006a-6b87-49d2-8d26-de34174ebda1">6.1</a>). </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-888-838-2872, X6351 or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
<p class="Highlighta"><span class="Italics">Pediatric use information for patients ages 6 to 14 years  of age for acute prevention of exercise-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> (EIB)  is approved for Merck Sharp &amp; Dohme Corpâ€™s montelukast tablet products.  However, due to Merck Sharp &amp; Dohme Corpâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div>
<div><div></div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span> (EIB) in Patients 15 Years of Age and Older</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> and <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Concomitant Corticosteroid Use</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Aspirin Sensitivity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Neuropsychiatric Events</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Eosinophilic Conditions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span> (EIB)</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span> (Seasonal and Perennial)</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">Storage</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Information for Patients</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 FDA-Approved Patient Labeling</a></h2>
<h2><a href="#section-17.1" class="toc">Montelukast Sodium Tablets 10 mg Label Text</a></h2>
<h2><a href="#section-18.1" class="toc">Montelukast Sodium Chewable Tablets 4 mg Label Text</a></h2>
<h2><a href="#section-19.1" class="toc">Montelukast Sodium Chewable Tablets 5 mg Label Text</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_0941bd56-2410-4d2c-8705-f23e5866161a"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_28894606-e746-4382-a678-5aa3b31b7edc"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Montelukast sodium is indicated for the prophylaxis and chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in adults and pediatric patients 12 months of age and older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ba0e1d5-0bef-4262-86fa-9398cf6026fe"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span></h2>
<p class="First">Montelukast sodium is indicated for prevention of exercise-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> (EIB) in patients 15 years of age and older.</p>
<p><span class="Italics">Pediatric use information for patients ages 6 to 14 years  of age for acute prevention of  exercise-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> (EIB)  is approved for Merck Sharp &amp; Dohme Corpâ€™s montelukast tablet products.  However, due to Merck Sharp &amp; Dohme Corpâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_82879b0a-3bef-48c8-bdef-e720d270f03e"></a><a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span></h2>
<p class="First">Montelukast sodium is indicated for the relief of symptoms of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> in patients 2 years of age and older and <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> in patients 6 months of age and older.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_4f311a68-e4df-43bb-b7fa-d35c9fe4d0a2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_03ab470c-0533-49ef-88da-18f7ffea21f5"></a><a name="section-2.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Montelukast sodium should be taken once daily in the evening. The following doses are recommended:</p>
<p>For adults and adolescents 15 years of age and older: one 10 mg tablet.</p>
<p>For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.</p>
<p>For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.</p>
<p>Safety and effectiveness in pediatric patients less than 12 months of age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> have not been established.</p>
<p>There have been no clinical trials in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> to evaluate the relative efficacy of morning versus evening dosing. The pharmacokinetics of montelukast are similar whether dosed in the morning or evening. Efficacy has been demonstrated for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> when montelukast was administered in the evening without regard to time of food ingestion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5eec40d0-9b4f-477f-b7bc-459431c3ea2e"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span> (EIB) in Patients 15 Years of Age and Older</h2>
<p class="First">Â For prevention of EIB, a single 10 mg dose of montelukast should be taken at least 2 hours before exercise. An additional dose of montelukast should not be taken within 24 hours of a previous dose. Patients already taking montelukast sodium daily for another indication (including chronic <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>) should not take an additional dose to prevent EIB. All patients should have available for rescue a short-acting Î²-agonist. Safety and effectiveness in patients younger than 15 years of age have not been established. Daily administration of montelukast sodium for the chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has not been established to prevent acute episodes of EIB.</p>
<p><span class="Italics">Pediatric use information for patients ages 6 to 14 years  of age for acute prevention of  exercise-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> (EIB)  is approved for Merck Sharp &amp; Dohme Corpâ€™s montelukast tablet products.  However, due to Merck Sharp &amp; Dohme Corpâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2670796a-9627-43c9-9d39-f54f0e505953"></a><a name="section-2.3"></a><p></p>
<h2>2.3 <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span></h2>
<p class="First">For <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>, montelukast sodium should be taken once daily. Efficacy was demonstrated for <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> when montelukast was administered in the morning or the evening without regard to time of food ingestion. The time of administration may be individualized to suit patient needs.</p>
<p>The following doses for the treatment of symptoms of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> are recommended:</p>
<p>For adults and adolescents 15 years of age and older: one 10 mg tablet.</p>
<p>For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.</p>
<p>For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.</p>
<p>Safety and effectiveness in pediatric patients younger than 2 years of age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> have not been established.</p>
<p>The following doses for the treatment of symptoms of <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> are recommended:</p>
<p>For adults and adolescents 15 years of age and older: one 10 mg tablet.</p>
<p>For pediatric patients 6 to 14 years of age: one 5 mg chewable tablet.</p>
<p>For pediatric patients 2 to 5 years of age: one 4 mg chewable tablet.</p>
<p>Safety and effectiveness in pediatric patients younger than 6 months of age with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e584c492-5623-4e7a-b443-6e30e6c29a3c"></a><a name="section-2.4"></a><p></p>
<h2>2.4 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> and <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span></h2>
<p class="First">Patients with both <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> should take only one montelukast sodium dose daily in the evening.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_fa3458c3-eb69-4df0-9045-3b8a14f854e8"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>Montelukast sodium film-coated tablets, 10 mg (montelukast) are beige, round, film-coated tablets, debossed with â€œTVâ€? on one side of the tablet and â€œ7426â€? on the other side.</li>
<li>Montelukast sodium chewable tablets, 4 mg (montelukast) are mottled pink, arc triangle-shaped tablets, debossed with â€œTVâ€? on one side of the tablet and â€œ7424â€?on the other side.</li>
<li>Montelukast sodium chewable tablets, 5 mg (montelukast) are mottled pink, square-shaped tablets, debossed with â€œTVâ€? on one side of the tablet and â€œ7425â€? on the other side.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_303a87a6-1288-437a-82ed-31c20a25ad3a"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_d37020bd-9ee1-4ee9-ad91-57cd554892d8"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cc82beeb-2c9e-4711-b41b-9b689d2c0e98"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Montelukast sodium is not indicated for use in the reversal of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks, including status asthmaticus. Patients should be advised to have appropriate rescue medication available. Therapy with montelukast sodium can be continued during acute exacerbations of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. Patients who have exacerbations of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> after exercise should have available for rescue a short-acting inhaled Î²-agonist.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8066a099-cd3a-402d-89c0-4aa47f774102"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Concomitant Corticosteroid Use</h2>
<p class="First">While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, montelukast sodium should not be abruptly substituted for inhaled or oral corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_513ae70f-5548-4576-b537-256c272abe2e"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Aspirin Sensitivity</h2>
<p class="First">Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium. Although montelukast sodium is effective in improving airway function in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatics</span> with documented aspirin sensitivity, it has not been shown to truncate bronchoconstrictor response to aspirin and other non-steroidal anti-inflammatory drugs in aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients [<span class="Italics">see Clinical Studies (<a href="#i4i_section_id_aa9dd216-51f1-4072-9150-aecf98ecb2f2">14.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bda8d701-d5f1-4df4-9fbf-4482043a56a9"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Neuropsychiatric Events</h2>
<p class="First">Neuropsychiatric events have been reported in adult, adolescent, and pediatric patients taking montelukast sodium. Postmarketing reports with montelukast sodium use include <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, anxiousness, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, dream abnormalities, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">somnambulism</span>, suicidal thinking and behavior (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>), and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. The clinical details of some postmarketing reports involving montelukast sodium appear consistent with a drug-induced effect.</p>
<p>Patients and prescribers should be alert for neuropsychiatric events. Patients should be instructed to notify their prescriber if these changes occur. Prescribers should carefully evaluate the risks and benefits of continuing treatment with montelukast sodium if such events occur [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_75766023-8edf-4555-8d0a-93d8264d5994">6.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0710497a-3f35-41c7-b6b6-ec0f0e50dfad"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Eosinophilic Conditions</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> on therapy with montelukast sodium may present with systemic <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, sometimes presenting with clinical features of <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These events usually, but not always, have been associated with the reduction of oral corticosteroid therapy. Physicians should be alert to <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4098878" conceptname="Vasculitic rash">vasculitic rash</span>, worsening pulmonary symptoms, cardiac complications, and/or <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> presenting in their patients. A causal association between montelukast sodium and these underlying conditions has not been established [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_75766023-8edf-4555-8d0a-93d8264d5994">6.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e5bd430c-d98c-44d5-8d23-9777274e7a08"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span></h2>
<p class="First">Phenylketonuric patients should be informed that the 4 mg and 5 mg chewable tablets contain phenylalanine (a component of aspartame), 0.28 mg in each 4 mg and 5 mg chewable tablet.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_c4828cb6-1085-4a1b-90bb-2dd91f46e46d"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b47b006a-6b87-49d2-8d26-de34174ebda1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In the following description of clinical trials experience, adverse reactions are listed regardless of causality assessment.</p>
<p>The most common adverse reactions (incidence â‰¥ 5% and greater than placebo; listed in descending order of frequency) in controlled clinical trials were: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>.</p>
<p><span class="Bold">Adults and Adolescents 15 Years of Age and Older with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>Montelukast sodium has been evaluated for safety in approximately 2950 adult and adolescent patients 15 years of age and older in clinical trials. In placebo-controlled clinical trials, the following adverse experiences reported with montelukast sodium occurred in greater than or equal to 1% of patients and at an incidence greater than that in patients treated with placebo:</p>
<a name="id_dab7a7a4-9fdd-4a9b-825c-2621972d6089"></a><table border="single" width="422">
<caption><span>Table 1: Adverse Experiences Occurring in â‰¥ 1% of Patients With an Incidence Greater Than That in Patients Treated With Placebo</span></caption>
<col width="41.7%">
<col width="42.4%">
<col width="15.9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">Montelukast 10 mg/day </td>
<td class="Botrule Rrule" align="center" valign="top">Placebo </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="top">(%)</td>
<td class="Botrule Rrule" align="center" valign="top">(%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="top">(n = 1955)</td>
<td class="Botrule Rrule" align="center" valign="top">(n = 1180)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Italics">Body As A Whole</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">     <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, abdominal </td>
<td class="Botrule Rrule" align="center" valign="top">2.9 </td>
<td class="Botrule Rrule" align="center" valign="top">2.5 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">     <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> </td>
<td class="Botrule Rrule" align="center" valign="top">1.8 </td>
<td class="Botrule Rrule" align="center" valign="top">1.2 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </td>
<td class="Botrule Rrule" align="center" valign="top">1.5 </td>
<td class="Botrule Rrule" align="center" valign="top">0.9 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Trauma</span></td>
<td class="Botrule Rrule" align="center" valign="top">1.0</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">0.8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Italics">Digestive System Disorders</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </td>
<td class="Botrule Rrule" align="center" valign="top">2.1 </td>
<td class="Botrule Rrule" align="center" valign="top">1.1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">     <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, dental </td>
<td class="Botrule Rrule" align="center" valign="top">1.7 </td>
<td class="Botrule Rrule" align="center" valign="top">1.0 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span>, infectious</td>
<td class="Botrule Rrule" align="center" valign="top">1.5 </td>
<td class="Botrule Rrule" align="center" valign="top">0.5 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Italics">Nervous System/Psychiatric</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td class="Botrule Rrule" align="center" valign="top">18.4 </td>
<td class="Botrule Rrule" align="center" valign="top">18.1 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td class="Botrule Rrule" align="center" valign="top">1.9 </td>
<td class="Botrule Rrule" align="center" valign="top">1.4 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">     <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span> </td>
<td class="Botrule Rrule" align="center" valign="top">4.2 </td>
<td class="Botrule Rrule" align="center" valign="top">3.9 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">     <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> </td>
<td class="Botrule Rrule" align="center" valign="top">2.7 </td>
<td class="Botrule Rrule" align="center" valign="top">2.4 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">     Congestion, nasal </td>
<td class="Botrule Rrule" align="center" valign="top">1.6 </td>
<td class="Botrule Rrule" align="center" valign="top">1.3 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Italics">Skin/Skin Appendages Disorder</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td class="Botrule Rrule" align="center" valign="top">1.6 </td>
<td class="Botrule Rrule" align="center" valign="top">1.2 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"><span class="Italics">Laboratory Adverse Experiences</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">     ALT increased </td>
<td class="Botrule Rrule" align="center" valign="top">2.1 </td>
<td class="Botrule Rrule" align="center" valign="top">2.0 </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">     AST increased </td>
<td class="Botrule Rrule" align="center" valign="top">1.6 </td>
<td class="Botrule Rrule" align="center" valign="top">1.2 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">     <span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">Pyuria</span> </td>
<td class="Rrule" align="center" valign="top">1.0 </td>
<td class="Botrule Rrule" align="center" valign="top">0.9 </td>
</tr>
</tbody>
</table>
<p>The frequency of less common adverse events was comparable between montelukast sodium and placebo.</p>
<p>The safety profile of montelukast sodium, when administered as a single dose for prevention of EIB in adult and adolescent patients 15 years of age and older, was consistent with the safety profile previously described for montelukast sodium.</p>
<p>Cumulatively, 569 patients were treated with montelukast sodium for at least 6 months, 480 for one year, and 49 for two years in clinical trials. With prolonged treatment, the adverse experience profile did not significantly change.</p>
<p><span class="Bold">Pediatric Patients 6 to 14 Years of Age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>Montelukast sodium has been evaluated for safety in 476 pediatric patients 6 to 14 years of age. Cumulatively, 289 pediatric patients were treated with montelukast sodium for at least 6 months, and 241 for one year or longer in clinical trials. The safety profile of montelukast sodium in the 8 week, double-blind, pediatric efficacy trial was generally similar to the adult safety profile. In pediatric patients 6 to 14 years of age receiving montelukast sodium, the following events occurred with a frequency â‰¥ 2% and more frequently than in pediatric patients who received placebo: <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, and <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>. The frequency of less common adverse events was comparable between montelukast sodium and placebo. With prolonged treatment, the adverse experience profile did not significantly change.</p>
<p><span class="Italics">Pediatric use information for patients ages 6 to 14 years  of age for acute prevention of  exercise-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> (EIB)  is approved for Merck Sharp &amp; Dohme Corpâ€™s montelukast tablet products.  However, due to Merck Sharp &amp; Dohme Corpâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
<p>In studies evaluating growth rate, the safety profile in these pediatric patients was consistent with the safety profile previously described for montelukast sodium. In a 56 week, double-blind study evaluating growth rate in pediatric patients 6 to 8 years of age receiving montelukast sodium, the following events not previously observed with the use of montelukast sodium in this age group occurred with a frequency â‰¥ 2% and more frequently than in pediatric patients who received placebo: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> (infective), <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">acute bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4322737" conceptname="Infection of tooth">tooth infection</span>, <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infection</span>, and <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span>.</p>
<p><span class="Bold">Pediatric Patients 2 to 5 Years of Age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>Montelukast sodium has been evaluated for safety in 573 pediatric patients 2 to 5 years of age in single- and multiple-dose studies. Cumulatively, 426 pediatric patients 2 to 5 years of age were treated with montelukast sodium for at least 3 months, 230 for 6 months or longer, and 63 patients for one year or longer in clinical trials. In pediatric patients 2 to 5 years of age receiving montelukast sodium, the following events occurred with a frequency â‰¥ 2% and more frequently than in pediatric patients who received placebo: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4183452" conceptname="Otitis">otitis</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, and <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
<p><span class="Bold">Pediatric Patients 6 to 23 Months of Age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>Safety and effectiveness in pediatric patients younger than 12 months of age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> have not been established.</p>
<p>Montelukast sodium has been evaluated for safety in 175 pediatric patients 6 to 23Â months of age. The safety profile of montelukast sodium in a 6 week, double-blind, placebo-controlled clinical study was generally similar to the safety profile in adults and pediatric patients 2 to 14Â years of age. In pediatric patients 6 to 23Â months of age receiving montelukast sodium, the following events occurred with a frequency â‰¥ 2% and more frequently than in pediatric patients who received placebo: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>; <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>; <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>; and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>. The frequency of less common adverse events was comparable between montelukast sodium and placebo.</p>
<p><span class="Bold">Adults and Adolescents 15 Years of Age and Older with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></span></p>
<p>Montelukast sodium has been evaluated for safety in 2199 adult and adolescent patients 15 years of age and older in clinical trials. Montelukast sodium administered once daily in the morning or in the evening had a safety profile similar to that of placebo. In placebo-controlled clinical trials, the following event was reported with montelukast sodium with a frequency â‰¥ 1% and at an incidence greater than placebo: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, 1.9% of patients receiving montelukast sodium vs. 1.5% of patients receiving placebo. In a 4 week, placebo-controlled clinical study, the safety profile was consistent with that observed in 2 week studies. The incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was similar to that of placebo in all studies.</p>
<p><span class="Bold">Pediatric Patients 2 to 14 Years of Age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></span></p>
<p>Montelukast sodium has been evaluated in 280 pediatric patients 2 to 14 years of age in a 2 week, multicenter, double-blind, placebo-controlled, parallel-group safety study. Montelukast sodium administered once daily in the evening had a safety profile similar to that of placebo. In this study, the following events occurred with a frequency â‰¥ 2% and at an incidence greater than placebo: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>.</p>
<p><span class="Bold">Adults and Adolescents 15 Years of Age and Older with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span> </span></p>
<p>Montelukast sodium has been evaluated for safety in 3357 adult and adolescent patients 15 years of age and older with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> of whom 1632 received montelukast sodium in two, 6 week, clinical studies. Montelukast sodium administered once daily had a safety profile consistent with that observed in patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> and similar to that of placebo. In these two studies, the following events were reported with montelukast sodium with a frequency â‰¥ 1% and at an incidence greater than placebo: <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="4172302" conceptname="Sinus headache">sinus headache</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and increased ALT. The incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was similar to that of placebo.</p>
<p><span class="Bold">Pediatric Patients 6 Months to 14 Years of Age with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></span></p>
<p>The safety in patients 2 to 14 years of age with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> is supported by the safety in patients 2 to 14 years of age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>. The safety in patients 6 to 23 months of age is supported by data from pharmacokinetic and safety and efficacy studies in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in this pediatric population and from adult pharmacokinetic studies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75766023-8edf-4555-8d0a-93d8264d5994"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of montelukast sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Blood and lymphatic system disorders: increased <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">bleeding tendency</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, hepatic eosinophilic infiltration.</p>
<p>Psychiatric disorders: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> including <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, anxiousness, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, dream abnormalities, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">somnambulism</span>, suicidal thinking and behavior (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>), <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_bda8d701-d5f1-4df4-9fbf-4482043a56a9">5.4</a>)</span>].</p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>/<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>: <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>.</p>
<p>Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>: <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Hepatobiliary disorders: Cases of <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span>, hepatocellular liver-injury, and mixed-pattern <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> have been reported in patients treated with montelukast sodium. Most of these occurred in combination with other confounding factors, such as use of other medications, or when montelukast sodium was administered to patients who had underlying potential for liver disease such as alcohol use or other forms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
<p>Skin and subcutaneous tissue disorders: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> including <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>.</p>
<p>General disorders and administration site conditions: <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> on therapy with montelukast sodium may present with systemic <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, sometimes presenting with clinical features of <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These events usually, but not always, have been associated with the reduction of oral corticosteroid therapy. Physicians should be alert to <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4098878" conceptname="Vasculitic rash">vasculitic rash</span>, worsening pulmonary symptoms, cardiac complications, and/or <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> presenting in their patients [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_0710497a-3f35-41c7-b6b6-ec0f0e50dfad">5.5</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_3ce40c3f-5caf-4557-8939-e30850d327c2"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No dose adjustment is needed when montelukast sodium is coadministered with theophylline, prednisone, prednisolone, oral contraceptives, terfenadine, digoxin, warfarin, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_8f05b24c-06b6-4c2f-9e7e-a0f0904809a3">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_97d2b207-1485-4282-8743-0d020f871c9b"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_41b2d303-7fd8-4783-a4a0-1c736d608d8d"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_20b5cbda-efd2-410d-ae7b-f06f624efa3f"></a><a name="section-8.1.1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_B_id_9e93d730-9057-4df9-b79c-b1b890bfa7f1"></a><a name="section-8.1.1.1"></a><p></p>
<h4>Pregnancy category B</h4>
<p class="First">There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, montelukast sodium should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_1cb0333e-962a-42ca-94de-19fe5df692f8"></a><a name="section-8.1.2"></a><p></p>
<h3>Teratogenic Effect</h3>
<p class="First">No <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed in rats and rabbits at doses approximately 100 and 110 times, respectively, the maximum recommended daily oral dose in adults based on AUCs [<span class="Italics">see Nonclinical Toxicology (<a href="#i4i_animal_pharmacology_id_c6a783ba-24dd-44d2-ad48-e8029db0216f">13.2</a>)</span>].</p>
<p>During worldwide marketing experience, congenital <span class="product-label-link" type="condition" conceptid="134741" conceptname="Congenital anomaly of limb">limb defects</span> have been rarely reported in the offspring of women being treated with montelukast sodium during pregnancy. Most of these women were also taking other <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> medications during their pregnancy. A causal relationship between these events and montelukast sodium has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_2a78499a-34fa-4d95-80af-cfd4568d8f80"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Studies in rats have shown that montelukast is excreted in milk. It is not known if montelukast is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when montelukast sodium is given to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_a6fafce8-c85c-4355-9a01-76d9f18a0891"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy of montelukast sodium have been established in adequate and well-controlled studies in pediatric patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> 6 to 14 years of age. Safety and efficacy profiles in this age group are similar to those seen in adults [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_b47b006a-6b87-49d2-8d26-de34174ebda1">6.1</a>), Clinical Pharmacology, Special Populations (<a href="#i4i_pharmacokinetics_id_8f05b24c-06b6-4c2f-9e7e-a0f0904809a3">12.3</a>), and Clinical Studies (<a href="#i4i_section_id_aa9dd216-51f1-4072-9150-aecf98ecb2f2">14.1</a>)</span>].</p>
<p>The efficacy of montelukast sodium for the treatment of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> in pediatric patients 2 to 14 years of age and for the treatment of <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> in pediatric patients 6 months to 14 years of age is supported by extrapolation from the demonstrated efficacy in patients 15 years of age and older with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> as well as the assumption that the disease course, pathophysiology and the drugâ€™s effect are substantially similar among these populations.</p>
<p>The safety of montelukast sodium chewable tablets, 4 mg in pediatric patients 2 to 5 years of age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been demonstrated by adequate and well-controlled data [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_b47b006a-6b87-49d2-8d26-de34174ebda1">6.1</a>)</span>]. Efficacy of montelukast sodium in this age group is extrapolated from the demonstrated efficacy in patients 6 years of age and older with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and is based on similar pharmacokinetic data, as well as the assumption that the disease course, pathophysiology and the drugâ€™s effect are substantially similar among these populations. Efficacy in this age group is supported by exploratory efficacy assessments from a large, well-controlled safety study conducted in patients 2 to 5 years of age.</p>
<p>The safety of montelukast sodium chewable tablets, 4 mg and 5 mg in pediatric patients aged 2 to 14 years with <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> is supported by data from studies conducted in pediatric patients aged 2 to 14 years with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. A safety study in pediatric patients 2 to 14 years of age with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> demonstrated a similar safety profile [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_b47b006a-6b87-49d2-8d26-de34174ebda1">6.1</a>)</span>]<span class="Italics">.</span></p>
<p>The safety and effectiveness in pediatric patients below the age of 12 months with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and 6Â months with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> have not been established. The safety and effectiveness in pediatric patients below the age of 6 years with exercise-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> have not been established.</p>
<p><span class="Italics">Pediatric use information for patients ages 6 to 14 years  of age for acute prevention of  exercise-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> (EIB)  is approved for Merck Sharp &amp; Dohme Corpâ€™s montelukast tablet products.  However, due to Merck Sharp &amp; Dohme Corpâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
<p><span class="Bold">Growth Rate in Pediatric Patients</span></p>
<p>A 56 week, multi-center, double-blind, randomized, active- and placebo-controlled parallel group study was conducted to assess the effect of montelukast sodium on growth rate in 360 patients with mild <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, aged 6 to 8 years. Treatment groups included montelukast 5 mg once daily, placebo, and beclomethasone dipropionate administered as 168 mcg twice daily with a spacer device. For each subject, a growth rate was defined as the slope of a linear regression line fit to the height measurements over 56 weeks. The primary comparison was the difference in growth rates between montelukast sodium and placebo groups. Growth rates, expressed as least-squares (LS) mean (95% CI) in cm/year, for the montelukast sodium, placebo, and beclomethasone treatment groups were 5.67 (5.46, 5.88), 5.64 (5.42, 5.86), and 4.86 (4.64, 5.08), respectively. The differences in growth rates, expressed as least-squares (LS) mean (95% CI) in cm/year, for montelukast sodium minus placebo, beclomethasone minus placebo, and montelukast sodium minus beclomethasone treatment groups were 0.03 (-0.26, 0.31), -0.78 (-1.06, -0.49); and 0.81 (0.53, 1.09), respectively. Growth rate (expressed as mean change in height over time) for each treatment group is shown in <span class="Bold">FIGURE 1</span>.</p>
<div class="Figure">
<img alt=" Figure 1: Change in Height (cm) From Randomization Visit by Scheduled Week (Treatment Group Mean Â± Standard Error of the Mean)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=09692f56-468c-4884-ae95-d2fb9d984e4c&amp;name=26dd1d17-c192-456a-af9b-307d3231363c-01.jpg"><p class="MultiMediaCaption">Figure 1: Change in Height (cm) From Randomization Visit by Scheduled Week (Treatment Group Mean Â± Standard Error<span class="Sup">â€ </span> of the Mean)</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_82a99a4d-118a-4ba6-bc3f-0eff85e0284c"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects in clinical studies of montelukast, 3.5% were 65 years of age and over, and 0.4% were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. The pharmacokinetic profile and the oral bioavailability of a single 10 mg oral dose of montelukast are similar in elderly and younger adults. The plasma half-life of montelukast is slightly longer in the elderly. No dosage adjustment in the elderly is required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b92c50a0-ce4e-4c37-adec-596c10800db8"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">No dosage adjustment is required in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_8f05b24c-06b6-4c2f-9e7e-a0f0904809a3">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ce9a11ae-16ed-4f48-98e3-0452f91a946c"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h2>
<p class="First">No dosage adjustment is recommended in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_8f05b24c-06b6-4c2f-9e7e-a0f0904809a3">12.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_e32a1801-65f4-4627-b4e6-e4c3367a61c2"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No mortality occurred following single oral doses of montelukast up to 5000Â mg/kg in mice (estimated exposure was approximately 335 and 210Â times the AUC for adults and children, respectively, at the maximum recommended daily oral dose) and rats (estimated exposure was approximately 230 and 145Â times the AUC for adults and children, respectively, at the maximum recommended daily oral dose).</p>
<p>No specific information is available on the treatment of overdosage with montelukast sodium. In chronic <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and, in short-term studies, up to 900 mg/day to patients for approximately a week without clinically important adverse experiences. In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, it is reasonable to employ the usual supportive measures; e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required.</p>
<p>There have been reports of acute overdosage in postmarketing experience and clinical studies with montelukast sodium. These include reports in adults and children with a dose as high as 1000 mg. The clinical and laboratory findings observed were consistent with the safety profile in adults and pediatric patients. There were no adverse experiences in the majority of overdosage reports. The most frequently occurring adverse experiences were consistent with the safety profile of montelukast sodium and included <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor hyperactivity</span>.</p>
<p>It is not known whether montelukast is removed by peritoneal dialysis or hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_45bb4df9-6a69-4a88-9234-7367d43f9a09"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Montelukast sodium, the active ingredient in montelukast sodium tablets and montelukast sodium chewable tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT<span class="Sub">1</span> receptor.</p>
<p>Montelukast sodium is described chemically as [<span class="Italics">R</span>-(<span class="Italics">E</span>)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid, monosodium salt.</p>
<p>The structural formula is:</p>
<div class="Figure"><img alt="montelukast sodium structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=09692f56-468c-4884-ae95-d2fb9d984e4c&amp;name=26dd1d17-c192-456a-af9b-307d3231363c-02.jpg"></div>
<p>C<span class="Sub">35</span>H<span class="Sub">35</span>ClNNaO<span class="Sub">3</span>S          M.W. 608.18</p>
<p>Montelukast sodium is a hygroscopic, optically active, white to off-white powder. Montelukast sodium is freely soluble in ethanol, methanol, and water and practically insoluble in acetonitrile.</p>
<p>Each 10 mg film-coated montelukast sodium tablet contains 10.4 mg montelukast sodium, which is equivalent to 10 mg of montelukast, and the following inactive ingredients: hydroxypropyl cellulose, hypromellose, iron oxide red, iron oxide yellow, lactose monohydrate (128.6 mg), magnesium stearate, pregelatinized starch, sodium lauryl sulfate, sodium starch glycolate, and titanium dioxide.</p>
<p>Each 4 mg and 5 mg montelukast sodium chewable tablet contains 4.2 and 5.2 mg montelukast sodium, respectively, which is equivalent to 4 and 5 mg of montelukast, respectively. Both chewable tablets contain the following inactive ingredients: aspartame, cherry flavoring [which contains maltodextrins (maize) and starch modified (waxy maize)], ferric oxide red, hydroxypropyl cellulose, magnesium stearate, mannitol granulate, sodium lauryl sulfate, and sodium starch glycolate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_5daa25bb-dac5-4b6a-9616-e9ec68fa4b1b"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_87ca8247-2e8e-4d58-878f-5b4ab01488a9"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The cysteinyl leukotrienes (LTC<span class="Sub">4</span>, LTD<span class="Sub">4</span>, LTE<span class="Sub">4</span>) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT<span class="Sub">1</span>) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>. In <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, leukotriene-mediated effects include airway <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>.</p>
<p>Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT<span class="Sub">1</span> receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or Î²-adrenergic receptor). Montelukast inhibits physiologic actions of LTD<span class="Sub">4</span> at the CysLT<span class="Sub">1</span> receptor without any agonist activity.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_da655e43-62fa-4222-be8b-c8c8b399a33b"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> due to inhaled LTD<span class="Sub">4</span> in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatics</span>. Doses as low as 5 mg cause substantial blockage of LTD<span class="Sub">4</span>-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span>. In a placebo-controlled, crossover study (n = 12), montelukast sodium inhibited early- and late-phase <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> due to antigen challenge by 75% and 57%, respectively.</p>
<p>The effect of montelukast sodium on eosinophils in the peripheral blood was examined in clinical trials. In patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> aged 2 years and older who received montelukast sodium, a decrease in mean peripheral blood eosinophil counts ranging from 9% to 15% was noted, compared with placebo, over the double-blind treatment periods. In patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> aged 15 years and older who received montelukast sodium, a mean increase of 0.2% in peripheral blood eosinophil counts was noted, compared with a mean increase of 12.5% in placebo-treated patients, over the double-blind treatment periods; this reflects a mean difference of 12.3% in favor of montelukast sodium. The relationship between these observations and the clinical benefits of montelukast noted in the clinical trials is not known [<span class="Italics">see Clinical Studies (<a href="#i4i_clinical_studies_id_85e538c7-5d19-424e-90ea-5695311b79f4">14</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_8f05b24c-06b6-4c2f-9e7e-a0f0904809a3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption </span></span></p>
<p>Montelukast is rapidly absorbed following oral administration. After administration of the 10 mg film-coated tablet to fasted adults, the mean peak montelukast plasma concentration (C<span class="Sub">max</span>) is achieved in 3 to 4 hours (T<span class="Sub">max</span>). The mean oral bioavailability is 64%. The oral bioavailability and C<span class="Sub">max</span> are not influenced by a standard meal in the morning.</p>
<p>For the 5 mg chewable tablet, the mean C<span class="Sub">max</span> is achieved in 2 to 2.5 hours after administration to adults in the fasted state. The mean oral bioavailability is 73% in the fasted state versus 63% when administered with a standard meal in the morning.</p>
<p>For the 4 mg chewable tablet, the mean C<span class="Sub">max</span> is achieved 2 hours after administration in pediatric patients 2 to 5 years of age in the fasted state.</p>
<p>The safety and efficacy of montelukast sodium in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> were demonstrated in clinical trials in which the 10 mg film-coated tablet and 5 mg chewable tablet formulations were administered in the evening without regard to the time of food ingestion. The safety of montelukast sodium in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> was also demonstrated in clinical trials in which the 4 mg chewable tablet formulation was administered in the evening without regard to the time of food ingestion. The safety and efficacy of montelukast sodium in patients with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> were demonstrated in clinical trials in which the 10 mg film-coated tablet was administered in the morning or evening without regard to the time of food ingestion.</p>
<p>The comparative pharmacokinetics of montelukast when administered as two 5 mg chewable tablets versus one 10 mg film-coated tablet have not been evaluated.</p>
<p><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Montelukast is more than 99% bound to plasma proteins. The steady state volume of distribution of montelukast averages 8 to 11 liters. Studies in rats with radiolabeled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabeled material at 24 hours postdose were minimal in all other tissues.</p>
<p><span class="Bold"><span class="Italics">Metabolism</span></span></p>
<p>Montelukast is extensively metabolized. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and pediatric patients.</p>
<p><span class="Italics">In vitro</span> studies using human liver microsomes indicate that CYP3A4 and 2C9 are involved in the metabolism of montelukast. Clinical studies investigating the effect of known inhibitors of CYP3A4 (e.g., ketoconazole, erythromycin) or 2C9 (e.g., fluconazole) on montelukast pharmacokinetics have not been conducted. Based on further <span class="Italics">in vitro</span> results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit CYP3A4, 2C9, 1A2, 2A6, 2C19, or 2D6 [<span class="Italics">see Drug Interactions (<a href="#i4i_interactions_id_3ce40c3f-5caf-4557-8939-e30850d327c2">7</a>) and Clinical Pharmacology, Drug-Drug Interactions (<a href="#i4i_pharmacokinetics_id_8f05b24c-06b6-4c2f-9e7e-a0f0904809a3">12.3</a>)</span>]. <span class="Italics">In vitro</span> studies have shown that montelukast is a potent inhibitor of CYP2C8; however, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 <span class="Italics">in vivo</span>, and therefore is not anticipated to alter the metabolism of drugs metabolized by this enzyme [<span class="Italics">see Drug Interactions (<a href="#i4i_interactions_id_3ce40c3f-5caf-4557-8939-e30850d327c2">7</a>) and Clinical Pharmacology, Drug-Drug Interactions (<a href="#i4i_pharmacokinetics_id_8f05b24c-06b6-4c2f-9e7e-a0f0904809a3">12.3</a>)</span>].</p>
<p><span class="Bold"><span class="Italics">Elimination</span></span></p>
<p>The plasma clearance of montelukast averages 45 mL/min in healthy adults. Following an oral dose of radiolabeled montelukast, 86% of the radioactivity was recovered in 5 day fecal collections and &lt; 0.2% was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.</p>
<p>In several studies, the mean plasma half-life of montelukast ranged from 2.7 to 5.5 hours in healthy young adults. The pharmacokinetics of montelukast are nearly linear for oral doses up to 50 mg. During once-daily dosing with 10 mg montelukast, there is little accumulation of the parent drug in plasma (14%).</p>
<p><span class="Bold"><span class="Italics">Special Populations</span></span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>:</span> Patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> and clinical evidence of cirrhosis had evidence of decreased metabolism of montelukast resulting in 41% (90% CI = 7%, 85%) higher mean montelukast AUC following a single 10 mg dose. The elimination of montelukast was slightly prolonged compared with that in healthy subjects (mean half-life, 7.4 hours). No dosage adjustment is required in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>. The pharmacokinetics of montelukast sodium in patients with more severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have not been evaluated.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>:</span> Since montelukast and its metabolites are not excreted in the urine, the pharmacokinetics of montelukast were not evaluated in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. No dosage adjustment is recommended in these patients.</p>
<p><span class="Italics">Gender:</span> The pharmacokinetics of montelukast are similar in males and females.</p>
<p><span class="Italics">Race:</span> Pharmacokinetic differences due to race have not been studied.</p>
<p><span class="Italics">Adolescents and Pediatric Patients:</span> Pharmacokinetic studies evaluated the systemic exposure of the 4 mg chewable tablets in pediatric patients 2 to 5 years of age, the 5 mg chewable tablets in pediatric patients 6 to 14 years of age, and the 10 mg film-coated tablets in young adults and adolescents â‰¥ 15 years of age.</p>
<p>The plasma concentration profile of montelukast following administration of the 10 mg film-coated tablet is similar in adolescents â‰¥ 15 years of age and young adults. The 10 mg film-coated tablet is recommended for use in patients â‰¥ 15 years of age.</p>
<p>The mean systemic exposure of the 4 mg chewable tablet in pediatric patients 2 to 5 years of age and the 5 mg chewable tablets in pediatric patients 6 to 14 years of age is similar to the mean systemic exposure of the 10 mg film-coated tablet in adults. The 5 mg chewable tablet should be used in pediatric patients 6 to 14 years of age and the 4 mg chewable tablet should be used in pediatric patients 2 to 5 years of age.</p>
<p>In children 6 to 11Â months of age, the systemic exposure to montelukast and the variability of plasma montelukast concentrations were higher than those observed in adults. Based on population analyses, the mean AUC (4296Â ngâ€¢hr/mL [range 1200 to 7153]) was 60% higher and the mean C<span class="Sub">max</span> (667Â ng/mL [range 201 to 1058]) was 89% higher than those observed in adults (mean AUC 2689Â ngâ€¢hr/mL [range 1521 to 4595]) and mean C<span class="Sub">max</span> (353Â ng/mL [range 180 to 548]). The systemic exposure in children 12 to 23Â months of age was less variable, but was still higher than that observed in adults. The mean AUC (3574Â ngâ€¢hr/mL [range 2229 to 5408]) was 33% higher and the mean C<span class="Sub">max</span> (562Â ng/mL [range 296 to 814]) was 60% higher than those observed in adults. Safety and tolerability of montelukast in a single-dose pharmacokinetic study in 26 children 6 to 23 months of age were similar to that of patients two years and above [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_b47b006a-6b87-49d2-8d26-de34174ebda1">6.1</a>)</span>]<span class="Italics">.</span></p>
<p><span class="Bold"><span class="Italics">Drug-Drug Interactions</span></span></p>
<p><span class="Italics">Theophylline, Prednisone, and Prednisolone:</span> Montelukast sodium has been administered with other therapies routinely used in the prophylaxis and chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> with no apparent increase in adverse reactions. In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, and prednisolone.</p>
<p>Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state, did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline [predominantly a cytochrome P450 (CYP) 1A2 substrate]. Montelukast at doses of â‰¥ 100 mg daily dosed to pharmacokinetic steady state, did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.</p>
<p><span class="Italics">Oral Contraceptives, Terfenadine, Digoxin, and Warfarin:</span> In drug interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. Montelukast at doses of â‰¥ 100 mg daily dosed to pharmacokinetic steady state did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. Montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state did not change the plasma concentration profile of terfenadine (a substrate of CYP3A4) or fexofenadine, the carboxylated metabolite, and did not prolong the QT<span class="Sub">c</span> interval following coadministration with terfenadine 60 mg twice daily; did not change the pharmacokinetic profile or urinary excretion of immunoreactive digoxin; did not change the pharmacokinetic profile of warfarin (primarily a substrate of CYP2C9, 3A4 and 1A2) or influence the effect of a single 30 mg oral dose of warfarin on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time or the International Normalized Ratio (INR).</p>
<p><span class="Italics">Thyroid Hormones, Sedative Hypnotics, Non-Steroidal Anti-Inflammatory Agents, Benzodiazepines, and Decongestants:</span> Although additional specific interaction studies were not performed, montelukast was used concomitantly with a wide range of commonly prescribed drugs in clinical studies without evidence of clinical adverse interactions. These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.</p>
<p><span class="Italics">Cytochrome P450 (CYP) Enzyme Inducers:</span> Phenobarbital, which induces hepatic metabolism, decreased the area under the plasma concentration curve (AUC) of montelukast approximately 40% following a single 10 mg dose of montelukast. No dosage adjustment for montelukast sodium is recommended. It is reasonable to employ appropriate clinical monitoring when potent CYP enzyme inducers, such as phenobarbital or rifampin, are coadministered with montelukast sodium.</p>
<p>Montelukast is a potent inhibitor of CYP2C8 <span class="Italics">in vitro</span>. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) in 12 healthy individuals demonstrated that the pharmacokinetics of rosiglitazone are not altered when the drugs are coadministered, indicating that montelukast does not inhibit CYP2C8 <span class="Italics">in vivo</span>. Therefore, montelukast is not anticipated to alter the metabolism of drugs metabolized by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide).</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_470532d6-4dcf-4306-b59a-1c8a67fcdadc"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_76f68e90-a1b3-47a2-9b30-811480ac607a"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No evidence of tumorigenicity was seen in carcinogenicity studies of either 2 years in Sprague-Dawley rats or 92 weeks in mice at oral gavage doses up to 200 mg/kg/day or 100 mg/kg/day, respectively. The estimated exposure in rats was approximately 120 and 75 times the AUC for adults and children, respectively, at the maximum recommended daily oral dose. The estimated exposure in mice was approximately 45 and 25 times the AUC for adults and children, respectively, at the maximum recommended daily oral dose.</p>
<p>Montelukast demonstrated no evidence of mutagenic or clastogenic activity in the following assays: the microbial mutagenesis assay, the V-79 mammalian cell mutagenesis assay, the alkaline elution assay in rat hepatocytes, the chromosomal aberration assay in Chinese hamster ovary cells, and in the <span class="Italics">in vivo</span> mouse bone marrow chromosomal aberration assay.</p>
<p>In fertility studies in female rats, montelukast produced reductions in fertility and fecundity indices at an oral dose of 200 mg/kg (estimated exposure was approximately 70 times the AUC for adults at the maximum recommended daily oral dose). No effects on female fertility or fecundity were observed at an oral dose of 100 mg/kg (estimated exposure was approximately 20 times the AUC for adults at the maximum recommended daily oral dose). Montelukast had no effects on fertility in male rats at oral doses up to 800 mg/kg (estimated exposure was approximately 160 times the AUC for adults at the maximum recommended daily oral dose).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_c6a783ba-24dd-44d2-ad48-e8029db0216f"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="Bold">Reproductive Toxicology Studies</span></p>
<p>No <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed at oral doses up to 400 mg/kg/day and 300 mg/kg/day in rats and rabbits, respectively. These doses were approximately 100 and 110 times the maximum recommended daily oral dose in adults, respectively, based on AUCs. Montelukast crosses the placenta following oral dosing in rats and rabbits [<span class="Italics">see Use in Specific Populations (<a href="#i4i_pregnancy_id_41b2d303-7fd8-4783-a4a0-1c736d608d8d">8.1</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_85e538c7-5d19-424e-90ea-5695311b79f4"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa9dd216-51f1-4072-9150-aecf98ecb2f2"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First"><span class="Bold">Adults and Adolescents 15 Years of Age and Older with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>Clinical trials in adults and adolescents 15 years of age and older demonstrated there is no additional clinical benefit to montelukast doses above 10 mg once daily.</p>
<p>The efficacy of montelukast sodium for the chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in adults and adolescents 15 years of age and older was demonstrated in two (U.S. and Multinational) similarly designed, randomized, 12 week, double-blind, placebo-controlled trials in 1576 patients (795 treated with montelukast sodium, 530 treated with placebo, and 251 treated with active control). The median age was 33 years (range 15 to 85); 56.8% were females and 43.2% were males. The ethnic/racial distribution in these studies was 71.6% Caucasian, 17.7% Hispanic, 7.2% other origins and 3.5% Black. Patients had mild or moderate <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and were non-smokers who required approximately 5 puffs of inhaled Î²-agonist per day on an â€œas-neededâ€? basis. The patients had a mean baseline percent of predicted forced expiratory volume in 1 second (FEV<span class="Sub">1</span>) of 66% (approximate range, 40 to 90%). The co-primary endpoints in these trials were FEV<span class="Sub">1</span> and daytime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms. In both studies after 12 weeks, a random subset of patients receiving montelukast sodium was switched to placebo for an additional 3 weeks of double-blind treatment to evaluate for possible rebound effects.</p>
<p>The results of the U.S. trial on the primary endpoint, morning FEV<span class="Sub">1</span>, expressed as mean percent change from baseline averaged over the 12 week treatment period, are shown in <span class="Bold">FIGURE 2</span>. Compared with placebo, treatment with one montelukast sodium tablet, 10 mg daily in the evening resulted in a statistically significant increase in FEV<span class="Sub">1</span> percent change from baseline (13.0% change in the group treated with montelukast sodium vs. 4.2% change in the placebo group, p &lt; 0.001); the change from baseline in FEV<span class="Sub">1</span> for montelukast sodium was 0.32 liters compared with 0.10 liters for placebo, corresponding to a between-group difference of 0.22 liters (p &lt; 0.001, 95% CI 0.17 liters, 0.27 liters). The results of the Multinational trial on FEV<span class="Sub">1</span> were similar.</p>
<div class="Figure">
<img alt=" Figure 2: FEV1 Mean Percent Change From Baseline (U.S. Trial: Montelukast Sodium N = 406; Placebo N = 270) (ANOVA Model)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=09692f56-468c-4884-ae95-d2fb9d984e4c&amp;name=26dd1d17-c192-456a-af9b-307d3231363c-03.jpg"><p class="MultiMediaCaption">Figure 2: FEV<span class="Sub">1</span> Mean Percent Change From Baseline (U.S. Trial: Montelukast Sodium N = 406; Placebo N = 270) (ANOVA Model)</p>
</div>
<p>The effect of montelukast sodium on other primary and secondary endpoints, represented by the Multinational study is shown in <span class="Bold">TABLE 2</span>. Results on these endpoints were similar in the U.S. study.</p>
<a name="id_c0dc916f-e52d-4536-b32c-52e5da0dbed8"></a><table border="single" width="428">
<caption><span>Table 2: Effect of Montelukast Sodium on Primary and Secondary Endpoints in a Multinational Placebo-Controlled Trial (ANOVA Model)</span></caption>
<col width="25.9%">
<col width="8.6%">
<col width="11.4%">
<col width="16.6%">
<col width="9.1%">
<col width="11.7%">
<col width="16.6%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>p &lt; 0.001, compared with placebo</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">Montelukast Sodium </td>
<td class="Botrule Rrule" align="center" colspan="3" valign="top">Placebo </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Endpoint </td>
<td class="Botrule Rrule" align="center" valign="top">N</td>
<td class="Botrule Rrule" align="center" valign="top">Baseline</td>
<td class="Botrule Rrule" align="center" valign="top">Mean Change from Baseline</td>
<td class="Botrule Rrule" align="center" valign="top">N</td>
<td class="Botrule Rrule" align="center" valign="top">Baseline</td>
<td class="Botrule Rrule" align="center" valign="top">Mean Change from Baseline</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Daytime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> Symptoms (0 to 6 scale) </td>
<td class="Botrule Rrule" align="center" valign="top">372</td>
<td class="Botrule Rrule" align="center" valign="top">2.35</td>
<td class="Botrule Rrule" align="center" valign="top">-0.49<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">245</td>
<td class="Botrule Rrule" align="center" valign="top">2.40</td>
<td class="Botrule Rrule" align="center" valign="top">-0.26</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Î²-agonist (puffs per day) </td>
<td class="Botrule Rrule" align="center" valign="top">371</td>
<td class="Botrule Rrule" align="center" valign="top">5.35</td>
<td class="Botrule Rrule" align="center" valign="top">-1.65<a href="#footnote-1" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">241</td>
<td class="Botrule Rrule" align="center" valign="top">5.78</td>
<td class="Botrule Rrule" align="center" valign="top">-0.42</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">AM PEFR (L/min) </td>
<td class="Botrule Rrule" align="center" valign="middle">372</td>
<td class="Botrule Rrule" align="center" valign="middle">339.57</td>
<td class="Botrule Rrule" align="center" valign="middle">25.03<a href="#footnote-1" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="middle">244</td>
<td class="Botrule Rrule" align="center" valign="middle">335.24</td>
<td class="Botrule Rrule" align="center" valign="middle">1.83</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">PM PEFR (L/min) </td>
<td class="Botrule Rrule" align="center" valign="middle">372</td>
<td class="Botrule Rrule" align="center" valign="middle">355.23</td>
<td class="Botrule Rrule" align="center" valign="middle">20.13<a href="#footnote-1" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="middle">244</td>
<td class="Botrule Rrule" align="center" valign="middle">354.02</td>
<td class="Botrule Rrule" align="center" valign="middle">-0.49</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">Nocturnal Awakenings (#/week) </td>
<td class="Rrule" align="center" valign="middle">285</td>
<td class="Rrule" align="center" valign="middle">5.46</td>
<td class="Rrule" align="center" valign="middle">-2.03<a href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center" valign="middle">195</td>
<td class="Rrule" align="center" valign="middle">5.57</td>
<td class="Botrule Rrule" align="center" valign="middle">-0.78</td>
</tr>
</tbody>
</table>
<p>Both studies evaluated the effect of montelukast sodium on secondary outcomes, including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack (utilization of health-care resources such as an unscheduled visit to a doctor's office, emergency room, or hospital; or treatment with oral, intravenous, or intramuscular corticosteroid), and use of oral corticosteroids for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> rescue. In the Multinational study, significantly fewer patients (15.6% of patients) on montelukast sodium experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks compared with patients on placebo (27.3%, p &lt; 0.001). In the U.S. study, 7.8% of patients on montelukast sodium and 10.3% of patients on placebo experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks, but the difference between the two treatment groups was not significant (p = 0.334). In the Multinational study, significantly fewer patients (14.8% of patients) on montelukast sodium were prescribed oral corticosteroids for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> rescue compared with patients on placebo (25.7%, p &lt; 0.001). In the U.S. study, 6.9% of patients on montelukast sodium and 9.9% of patients on placebo were prescribed oral corticosteroids for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> rescue, but the difference between the two treatment groups was not significant (p = 0.196).</p>
<p><span class="Bold">Onset of Action and Maintenance of Effects</span></p>
<p>In each placebo-controlled trial in adults, the treatment effect of montelukast sodium, measured by daily diary card parameters, including symptom scores, â€œas-neededâ€? Î²-agonist use, and PEFR measurements, was achieved after the first dose and was maintained throughout the dosing interval (24 hours). No significant change in treatment effect was observed during continuous once-daily evening administration in non-placebo-controlled extension trials for up to one year. Withdrawal of montelukast sodium in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients after 12 weeks of continuous use did not cause rebound worsening of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p><span class="Bold">Pediatric Patients 6 to 14 Years of Age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>The efficacy of montelukast sodium in pediatric patients 6 to 14 years of age was demonstrated in one 8 week, double-blind, placebo-controlled trial in 336 patients (201 treated with montelukast sodium and 135 treated with placebo) using an inhaled Î²-agonist on an â€œas-neededâ€? basis. The patients had a mean baseline percent predicted FEV<span class="Sub">1</span> of 72% (approximate range, 45 to 90%) and a mean daily inhaled Î²-agonist requirement of 3.4 puffs of albuterol. Approximately 36% of the patients were on inhaled corticosteroids. The median age was 11 years (range 6 to 15); 35.4% were females and 64.6% were males. The ethnic/racial distribution in this study was 80.1% Caucasian, 12.8% Black, 4.5% Hispanic, and 2.7% other origins.</p>
<p>Compared with placebo, treatment with one montelukast sodium chewable tablet, 5 mg daily resulted in a significant improvement in mean morning FEV<span class="Sub">1</span> percent change from baseline (8.7% in the group treated with montelukast sodium vs. 4.2% change from baseline in the placebo group, p &lt; 0.001). There was a significant decrease in the mean percentage change in daily â€œas-neededâ€? inhaled Î²-agonist use (11.7% decrease from baseline in the group treated with montelukast sodium vs. 8.2% increase from baseline in the placebo group, p &lt; 0.05). This effect represents a mean decrease from baseline of 0.56 and 0.23 puffs per day for the montelukast and placebo groups, respectively. Subgroup analyses indicated that younger pediatric patients aged 6 to 11 had efficacy results comparable to those of the older pediatric patients aged 12 to 14.</p>
<p>Similar to the adult studies, no significant change in the treatment effect was observed during continuous once-daily administration in one open-label extension trial without a concurrent placebo group for up to 6 months.</p>
<p><span class="Bold">Pediatric Patients 2 to 5 Years of Age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>The efficacy of montelukast sodium for the chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in pediatric patients 2 to 5 years of age was explored in a 12 week, placebo-controlled safety and tolerability study in 689 patients, 461 of whom were treated with montelukast sodium. The median age was 4 years (range 2 to 6); 41.5% were females and 58.5% were males. The ethnic/racial distribution in this study was 56.5% Caucasian, 20.9% Hispanic, 14.4% other origins, and 8.3% Black.</p>
<p>While the primary objective was to determine the safety and tolerability of montelukast sodium in this age group, the study included exploratory efficacy evaluations, including daytime and overnight <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptom scores, Î²-agonist use, oral corticosteroid rescue, and the physicianâ€™s global evaluation. The findings of these exploratory efficacy evaluations, along with pharmacokinetics and extrapolation of efficacy data from older patients, support the overall conclusion that montelukast sodium is efficacious in the maintenance treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in patients 2 to 5 years of age.</p>
<p><span class="Bold">Effects in Patients on Concomitant Inhaled Corticosteroids</span></p>
<p>Separate trials in adults evaluated the ability of montelukast sodium to add to the clinical effect of inhaled corticosteroids and to allow inhaled corticosteroid tapering when used concomitantly.</p>
<p>One randomized, placebo-controlled, parallel-group trial (n = 226) enrolled adults with stable <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> with a mean FEV<span class="Sub">1</span> of approximately 84% of predicted who were previously maintained on various inhaled corticosteroids (delivered by metered-dose aerosol or dry powder inhalers). The median age was 41.5 years (range 16 to 70); 52.2% were females and 47.8% were males. The ethnic/racial distribution in this study was 92.0% Caucasian, 3.5% Black, 2.2% Hispanic, and 2.2% Asian. The types of inhaled corticosteroids and their mean baseline requirements included beclomethasone dipropionate (mean dose, 1203 mcg/day), triamcinolone acetonide (mean dose, 2004 mcg/day), flunisolide (mean dose, 1971 mcg/day), fluticasone propionate (mean dose, 1083 mcg/day), or budesonide (mean dose, 1192 mcg/day). Some of these inhaled corticosteroids were non-U.S.-approved formulations, and doses expressed may not be ex-actuator. The pre-study inhaled corticosteroid requirements were reduced by approximately 37% during a 5 to 7 week placebo run-in period designed to titrate patients toward their lowest effective inhaled corticosteroid dose. Treatment with montelukast sodium resulted in a further 47% reduction in mean inhaled corticosteroid dose compared with a mean reduction of 30% in the placebo group over the 12 week active treatment period (p â‰¤ 0.05). It is not known whether the results of this study can be generalized to patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> who require higher doses of inhaled corticosteroids or systemic corticosteroids.</p>
<p>In another randomized, placebo-controlled, parallel-group trial (n = 642) in a similar population of adult patients previously maintained, but not adequately controlled, on inhaled corticosteroids (beclomethasone 336 mcg/day), the addition of montelukast sodium to beclomethasone resulted in statistically significant improvements in FEV<span class="Sub">1</span> compared with those patients who were continued on beclomethasone alone or those patients who were withdrawn from beclomethasone and treated with montelukast or placebo alone over the last 10 weeks of the 16 week, blinded treatment period. Patients who were randomized to treatment arms containing beclomethasone had statistically significantly better <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> control than those patients randomized to montelukast sodium alone or placebo alone as indicated by FEV<span class="Sub">1</span>, daytime <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms, PEFR, nocturnal awakenings due to <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and â€œas-neededâ€? Î²-agonist requirements.</p>
<p>In adult patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> with documented aspirin sensitivity, nearly all of whom were receiving concomitant inhaled and/or oral corticosteroids, a 4 week, randomized, parallel-group trial (n = 80) demonstrated that montelukast sodium, compared with placebo, resulted in significant improvement in parameters of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> control. The magnitude of effect of montelukast sodium in aspirin-sensitive patients was similar to the effect observed in the general population of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> patients studied. The effect of montelukast sodium on the bronchoconstrictor response to aspirin or other non-steroidal anti-inflammatory drugs in aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients has not been evaluated [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_513ae70f-5548-4576-b537-256c272abe2e">5.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_25152ab1-68fe-46d4-acfa-989abf10c627"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span> (EIB)</h2>
<p class="First"><span class="Bold">Exercise-Induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchoconstriction</span> (Adults and Adolescents 15 years of age and older)</span></p>
<p>The efficacy of montelukast 10 mg, when given as a single dose 2 hours before exercise for the prevention of EIB was investigated in three (U.S. and Multinational), randomized, double-blind, placebo-controlled crossover studies that included a total of 160 adult and adolescent patients 15 years of age and older with EIB. Exercise challenge testing was conducted at 2 hours, 8.5 or 12 hours, and 24 hours following administration of a single dose of study drug (montelukast 10 mg or placebo). The primary endpoint was the mean maximum percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in FEV<span class="Sub">1</span> following the 2 hours post-dose exercise challenge in all three studies (Study A, Study B, and Study C). In Study A, a single dose of montelukast sodium 10 mg demonstrated a statistically significant protective benefit against EIB when taken 2 hours prior to exercise. Some patients were protected from EIB at 8.5 and 24 hours after administration; however, some patients were not. The results for the mean maximum percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> at each timepoint in Study A are shown in <span class="Bold">TABLE 3</span> and are representative of the results from the other two studies.</p>
<a name="id_02a6b37a-d8fe-4ddd-b40c-fb8d96342e5b"></a><table border="single" width="433">
<caption><span>Table 3: Mean Maximum Percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span> in FEV<span class="Sub">1</span> Following Exercise Challenge in Study A (N = 47) ANOVA Model</span></caption>
<col width="26.2%">
<col width="31.2%">
<col width="16.0%">
<col width="26.6%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Least squares-mean</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">Time of exercise challenge following medication administration</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">Mean Maximum percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in FEV<span class="Sub">1</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">Treatment difference % for Montelukast Sodium versus Placebo (95% CI)<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">Montelukast Sodium</td>
<td class="Botrule Rrule" align="center" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">2 hours</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
<td class="Botrule Rrule" align="center" valign="top">22</td>
<td class="Botrule Rrule" align="center" valign="top">-9 (-12, -5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">8.5 hours</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Rrule" align="center" valign="top">17</td>
<td class="Botrule Rrule" align="center" valign="top">-5 (-9, -2)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">24 hours</td>
<td class="Rrule" align="center" valign="top">10</td>
<td class="Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">-4 (-7, -1)</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Pediatric use information for patients ages 6 to 14 years  of age for acute prevention of  exercise-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> (EIB)  is approved for Merck Sharp &amp; Dohme Corpâ€™s montelukast tablet products.  However, due to Merck Sharp &amp; Dohme Corpâ€™s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
<p>The efficacy of montelukast sodium for prevention of EIB in patients below 6 years of age has not been established.</p>
<p>Daily administration of montelukast sodium for the chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has not been established to prevent acute episodes of EIB.</p>
<p>In a 12 week, randomized, double-blind, parallel group study of 110 adult and adolescent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatics</span> 15 years of age and older, with a mean baseline FEV<span class="Sub">1</span> percent of predicted of 83% and with documented exercise-induced <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, treatment with montelukast sodium, 10 mg, once daily in the evening, resulted in a statistically significant reduction in mean maximal percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in FEV<span class="Sub">1</span> and mean time to recovery to within 5% of the pre-exercise FEV<span class="Sub">1</span>. Exercise challenge was conducted at the end of the dosing interval (i.e., 20 to 24 hours after the preceding dose). This effect was maintained throughout the 12 week treatment period indicating that tolerance did not occur. Montelukast sodium did not, however, prevent clinically significant deterioration in maximal percent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in FEV<span class="Sub">1</span> after exercise (i.e., â‰¥ 20% decrease from pre-exercise baseline) in 52% of patients studied. In a separate crossover study in adults, a similar effect was observed after two once-daily 10 mg doses of montelukast sodium.</p>
<p>In pediatric patients 6 to 14Â years of age, using the 5 mg chewable tablet, a 2 day crossover study demonstrated effects similar to those observed in adults when exercise challenge was conducted at the end of the dosing interval (i.e., 20 to 24Â hours after the preceding dose).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_468269ea-2b4c-42c0-ba62-91fc677cd12a"></a><a name="section-13.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">Allergic Rhinitis</span> (Seasonal and Perennial)</h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span></span></p>
<p>The efficacy of montelukast sodium tablets for the treatment of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> was investigated in 5 similarly designed, randomized, double-blind, parallel-group, placebo- and active-controlled (loratadine) trials conducted in North America. The 5 trials enrolled a total of 5029 patients, of whom 1799 were treated with montelukast sodium tablets. Patients were 15 to 82 years of age with a history of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, a positive skin test to at least one relevant seasonal allergen, and active symptoms of <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span> at study entry.</p>
<p>The period of randomized treatment was 2 weeks in 4 trials and 4 weeks in one trial. The primary outcome variable was mean change from baseline in daytime nasal symptoms score (the average of individual scores of <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, nasal <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>) as assessed by patients on a 0 to 3 categorical scale.</p>
<p>Four of the five trials showed a significant reduction in daytime nasal symptoms scores with montelukast sodium tablets, 10 mg compared with placebo. The results of one trial are shown below. The median age in this trial was 35.0 years (range 15 to 81); 65.4% were females and 34.6% were males. The ethnic/racial distribution in this study was 83.1% Caucasian, 6.4% other origins, 5.8% Black, and 4.8% Hispanic. The mean changes from baseline in daytime nasal symptoms score in the treatment groups that received montelukast sodium tablets, loratadine, and placebo are shown in <span class="Bold">TABLE 4</span>. The remaining three trials that demonstrated efficacy showed similar results.</p>
<a name="id_11d281db-67fc-4293-92aa-f7dae9b174fd"></a><table border="single" width="428">
<caption><span>Table 4: Effects of Montelukast Sodium on Daytime Nasal Symptoms Score in a Placebo- and Active-Controlled Trial in Patients With <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">Seasonal Allergic Rhinitis</span> (ANCOVA Model)</span></caption>
<col width="25.4%">
<col width="16.8%">
<col width="25.2%">
<col width="32.6%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Statistically different from placebo (p â‰¤ 0.001).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Treatment Group (N)</td>
<td class="Botrule Rrule" align="center" valign="middle">Baseline Mean Score</td>
<td class="Botrule Rrule" align="center" valign="middle">Mean Change from Baseline</td>
<td class="Botrule Rrule" align="center" valign="top">Difference Between Treatment and Placebo (95% CI) Least-Squares Mean</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">Montelukast 10 mg</p>
<p>(344)</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">2.09</td>
<td class="Botrule Rrule" align="center" valign="middle">-0.39</td>
<td class="Botrule Rrule" align="center" valign="middle">-0.13<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> (-0.21, -0.06)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">Placebo</p>
<p>(351)</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">2.10</td>
<td class="Botrule Rrule" align="center" valign="middle">-0.26</td>
<td class="Botrule Rrule" align="center" valign="middle">N.A.</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Active Control
                                    </p>
<p>(Loratadine 10 mg)</p>
<p>(599)</p>
</td>
<td class="Rrule" align="center" valign="middle">2.06</td>
<td class="Rrule" align="center" valign="middle">-0.46</td>
<td class="Botrule Rrule" align="center" valign="middle">-0.24<a href="#footnote-3" class="Sup">*</a> (-0.31, -0.17)</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span></span></p>
<p>The efficacy of montelukast sodium tablets for the treatment of <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> was investigated in 2 randomized, double-blind, placebo-controlled studies conducted in North America and Europe. The two studies enrolled a total of 3357 patients, of whom 1632 received montelukast sodium tablets, 10 mg. Patients 15 to 82 years of age with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> as confirmed by history and a positive skin test to at least one relevant perennial allergen (dust mites, animal dander, and/or mold spores), who had active symptoms at the time of study entry, were enrolled.</p>
<p>In the study in which efficacy was demonstrated, the median age was 35 years (range 15 to 81); 64.1% were females and 35.9% were males. The ethnic/racial distribution in this study was 83.2% Caucasian, 8.1% Black, 5.4% Hispanic, 2.3% Asian, and 1.0% other origins. Montelukast sodium tablets, 10 mg once daily was shown to significantly reduce symptoms of <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span> over a 6 week treatment period (<span class="Bold">TABLE 5</span>); in this study the primary outcome variable was mean change from baseline in daytime nasal symptoms score (the average of individual scores of <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, and <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>).</p>
<a name="id_a123788a-4690-4e15-a1ba-9a50bc059f3a"></a><table border="single" width="397">
<caption><span>Table 5: Effects of Montelukast Sodium on Daytime Nasal Symptoms Score in a Placebo-Controlled Trial in Patients With <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">Perennial Allergic Rhinitis</span> (ANCOVA Model)</span></caption>
<col width="27.4%">
<col width="18.1%">
<col width="27.2%">
<col width="27.2%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Treatment Group (N)</td>
<td class="Botrule Rrule" align="center" valign="middle">Baseline Mean Score</td>
<td class="Botrule Rrule" align="center" valign="middle">Mean Change from Baseline</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Difference Between Treatment and Placebo (95% CI) Least-Squares Mean</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">Montelukast 10 mg</p>
<p>(1000)</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">2.09</td>
<td class="Botrule Rrule" align="center" valign="middle">-0.42</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">-0.08 (-0.12, -0.04)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">Placebo</p>
<p>(980)</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">2.10</td>
<td class="Botrule Rrule" align="center" valign="middle">-0.35</td>
<td class="Botrule Rrule" align="center" valign="middle">N.A.</td>
</tr>
</tbody>
</table>
<p>The other 6 week study evaluated montelukast 10 mg (n = 626), placebo (n = 609), and an active-control (cetirizine 10 mg; n = 120). The primary analysis compared the mean change from baseline in daytime nasal symptoms score for montelukast sodium vs. placebo over the first 4 weeks of treatment; the study was not designed for statistical comparison between montelukast sodium and the active-control. The primary outcome variable included nasal <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> in addition to <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, and <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>. The estimated difference between montelukast sodium and placebo was -0.04 with a 95% CI of (-0.09, 0.01). The estimated difference between the active-control and placebo was -0.10 with a 95% CI of (-0.19, -0.01).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_bdf62e73-5463-4f30-9cf1-dc12d81e4379"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Montelukast sodium tablets are available as:</p>
<p>10 mg (montelukast) â€“ beige, round, film-coated tablets, debossed with â€œTVâ€? on one side of the tablet and â€œ7426â€? on the other side, in <br></p>
<a name="i688133a9-5182-4bb8-883c-26a4a6c8e9aa"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>bottles of 30<br>
</td>
<td>NDC 54868-6361-0<br>
</td>
</tr>
<tr class="Last">
<td>bottles of 90<br>
</td>
<td>NDC 54868-6361-1<br>
</td>
</tr>
</tbody></table>
<p>Montelukast sodium chewable tablets are available as:</p>
<p>4 mg (montelukast) â€“ mottled pink, arc triangle-shaped tablets, debossed with â€œTVâ€? on one side of the tablet and â€œ7424â€?on the other side, in <br></p>
<a name="ifc31a54f-4bd6-4393-8bb4-27b090531748"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>bottles of 30<br>
</td>
<td>NDC 54868-6363-1<br>
</td>
</tr>
<tr class="Last">
<td>bottles of 60<br>
</td>
<td>NDC 54868-6363-0<br>
</td>
</tr>
</tbody></table>
<p>5 mg (montelukast) â€“ mottled pink, square-shaped tablets, debossed with â€œTVâ€? on one side of the tablet and â€œ7425â€? on the other side, in <br></p>
<a name="i9b0ec406-e8ec-476b-820b-0d40cc5a978d"></a><table width="30%"><tbody class="Headless"><tr class="First Last">
<td>bottles of 30<br>
</td>
<td>NDC 54868-6362-0<br>
</td>
</tr></tbody></table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_a78f57e7-4fbf-4538-b851-f3141ba6bdd4"></a><a name="section-14.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature]. Protect from moisture and light. Store in original package. </p>
<p><span class="Bold">Storage for Bulk Bottles</span></p>
<p>When product container is subdivided, repackage into a well-closed, light-resistant container.</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_5a1f4a01-2791-45f4-9beb-fb6ad4404b02"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">[<span class="Italics">See FDA-Approved Patient Labeling (17.2)</span><span class="Italics">.</span>]</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_268e4f61-46d8-422e-a547-ea64d8103548"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Information for Patients</h2>
<ul>
<li>Patients should be advised to take montelukast sodium daily as prescribed, even when they are asymptomatic, as well as during periods of worsening <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and to contact their physicians if their <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> is not well controlled.</li>
<li>Patients should be advised that oral montelukast sodium is not for the treatment of acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks. They should have appropriate short-acting inhaled Î²-agonist medication available to treat <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> exacerbations. Patients who have exacerbations of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> after exercise should be instructed to have available for rescue a short-acting inhaled Î²-agonist. Daily administration of montelukast sodium for the chronic treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has not been established to prevent acute episodes of EIB.</li>
<li>Patients should be advised that, while using montelukast sodium, medical attention should be sought if short-acting inhaled bronchodilators are needed more often than usual, or if more than the maximum number of inhalations of short-acting bronchodilator treatment prescribed for a 24 hour period are needed.</li>
<li>Patients receiving montelukast sodium should be instructed not to decrease the dose or stop taking any other anti-<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> medications unless instructed by a physician.</li>
<li>Patients should be instructed to notify their physician if neuropsychiatric events occur while using montelukast sodium.</li>
<li>Patients with known aspirin sensitivity should be advised to continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking montelukast sodium.</li>
<li>Phenylketonuric patients should be informed that the 4 mg and 5 mg chewable tablets contain phenylalanine (a component of aspartame).</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3b7cf774-f4e6-4cb6-a1f2-e98728a691ab"></a><a name="section-15.2"></a><p></p>
<h2>17.2 FDA-Approved Patient Labeling</h2>
<p class="First"><span class="Italics">See the full patient prescribing information for </span>montelukast sodium<span class="Italics">.</span></p>
<p>Manufactured In Israel By:</p>
<p><span class="Bold">TEVA PHARMACEUTICAL IND. LTD.</span></p>
<p>Jerusalem, 91010, Israel</p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Rev. C 7/2012</p>
<br><p><br></p>
<p><span class="Bold">Distributed and Repackaged by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OklahomaÂ Â Â Â Â Â  74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_0270dcd2-10f6-4fe8-8706-9e9f30efce89"></a><a name="section-16"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">Montelukast (mon-te-LOO-kast) Sodium Tablets and Chewable Tablets</span></p>
<p>Read the Patient Information Leaflet that comes with montelukast sodium tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">What is montelukast sodium?</span></p>
<ul><li>Montelukast sodium is a prescription medicine that blocks substances in the body called leukotrienes. This may help to improve symptoms of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>. Montelukast sodium does not contain a steroid.</li></ul>
<p>Montelukast sodium is used to:</p>
<ol>
<li>Prevent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks and for the long-term treatment of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in adults and children ages 12 months and older. Â <span class="Bold"><br>Do not take montelukast sodium if you need relief right away for a sudden <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack.</span> If you get an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, you should follow the instructions your healthcare provider gave you for treating <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks.</li>
<li>Prevent exercise-induced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in people 15 years of age and older.</li>
<li>Help control the symptoms of <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> (<span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, stuffy nose, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the nose). Montelukast sodium is used to treat:</li>
</ol>
<ul>
<li>outdoor allergies that happen part of the year (<span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>) in adults and children ages 2 years and older, <span class="Bold">and</span>
</li>
<li>indoor allergies that happen all year (<span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>) in adults and children ages 6 months and older.</li>
</ul>
<p><span class="Bold">Who should not take montelukast sodium?</span></p>
<p>Do not take montelukast sodium if you are allergic to any of its ingredients.</p>
<p>See the end of this leaflet for a complete list of the ingredients in montelukast sodium tablets and chewable tablets.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking montelukast sodium?</span></p>
<p><span class="Bold">Before taking montelukast sodium, tell your healthcare provider if you:</span></p>
<ul>
<li>are allergic to aspirin</li>
<li>have <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">phenylketonuria</span>. Montelukast sodium chewable tablets contain aspartame, a source of phenylalanine</li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. If you are pregnant or plan to become pregnant, montelukast sodium may not be right for you.</li>
<li>are breast-feeding or plan to breast-feed. It is not known if montelukast sodium passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking montelukast sodium.</li>
</ul>
<p>Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicines may affect how montelukast sodium works, or montelukast sodium may affect how your other medicines work.</p>
<p><span class="Bold">How should I take montelukast sodium?</span></p>
<p><span class="Bold">For anyone who takes montelukast sodium:</span></p>
<ul>
<li>Take montelukast sodium exactly as prescribed by your healthcare provider. Your healthcare provider will tell you how much montelukast sodium to take, and <span class="Bold">when to take it.</span>
</li>
<li>Do not stop taking montelukast sodium or change when you take it without talking with your healthcare provider.</li>
<li>You can take montelukast sodium with food or without food.</li>
<li>
<span class="Bold">If you or your child misses a dose of montelukast sodium, just take the next dose at your regular time.</span> Do not take 2 doses at the same time.</li>
<li>If you take too much montelukast sodium, call your doctor.</li>
</ul>
<p><span class="Bold">For adults and children 12 months of age and older with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>:</span></p>
<ul>
<li>Take montelukast sodium 1 time each day, in the evening. Continue to take montelukast sodium every day for as long as your healthcare provider prescribes it, even if you have no <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms.</li>
<li>Tell your healthcare provider right away if your <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms get worse, or if you need to use your rescue inhaler medicine more often for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks.</li>
<li>
<span class="Bold">Do not take montelukast sodium if you need relief right away from a sudden <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack.</span> If you get an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, you should follow the instructions your healthcare provider gave you for treating <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks.</li>
<li>Always have your rescue inhaler medicine with you for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks.</li>
<li>Do not stop taking or lower the dose of your other <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> medicines unless your healthcare provider tells you to.</li>
</ul>
<p><span class="Bold">For patients 15 years of age and older for the prevention of exercise-induced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>:</span></p>
<ul>
<li>Take montelukast sodium at least 2 hours before exercise.</li>
<li>Always have your rescue inhaler medicine with you for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks.</li>
<li>If you take montelukast sodium every day for chronic <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span>, <span class="Bold">do not</span> take another dose to prevent exercise-induced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. Talk to your healthcare provider about your treatment for exercise-induced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</li>
<li><span class="Bold">Do not take 2 doses of montelukast sodium within 24 hours (1 day).</span></li>
</ul>
<p><span class="Bold">For adults and children 2 years of age and older with <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, or for adults and children 6 months of age and older with <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span>:</span></p>
<ul><li>Take montelukast sodium 1 time each day, at about the same time each day.</li></ul>
<p><span class="Bold">What is the dose of montelukast sodium?</span></p>
<p>The dose of montelukast sodium prescribed for your or your child's condition is based on age:</p>
<p>â€¢ 2 to 5 years: one 4 mg chewable tablet.</p>
<p>â€¢ 6 to 14 years: one 5 mg chewable tablet.</p>
<p>â€¢ 15 years and older: one 10 mg tablet.</p>
<p><span class="Bold">What should I avoid while taking montelukast sodium?</span></p>
<p>If you have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and aspirin makes your <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms worse, continue to avoid taking aspirin or other medicines called non-steroidal anti-inflammatory drugs (NSAIDs) while taking montelukast sodium.</p>
<p><span class="Bold">What are the possible side effects of montelukast sodium?</span></p>
<p><span class="Bold">Montelukast sodium may cause serious side effects.</span></p>
<ul><li>
<span class="Bold">Behavior and mood-related changes.</span> Tell your healthcare provider right away if you or your child have any of these symptoms while taking montelukast sodium:<ul>
<li><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> including <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> or <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span></li>
<li>bad or <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span></li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li><span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> (<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>)</li>
<li>feeling anxious</li>
<li><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (seeing or hearing things that are not really there)</li>
<li><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></li>
<li><span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">sleep walking</span></li>
<li>suicidal thoughts and actions (including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></li>
<li>trouble sleeping</li>
</ul>
</li></ul>
<ul><li>
<span class="Bold">Increase in certain white blood cells (eosinophils) and possible inflamed blood vessels throughout the body (systemic <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>).</span> Rarely, this can happen in people with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> who take montelukast sodium. This usually, but not always, happens in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered.</li></ul>
<p><span class="Bold">Tell your healthcare provider right away if you get one or more of these symptoms:</span></p>
<ul><li><ul>
<li>a feeling of pins and needles or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> of arms or legs</li>
<li>a flu-like illness</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li>severe <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>) of the sinuses (<span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>)</li>
</ul></li></ul>
<p><span class="Bold">The most common side effects with montelukast sodium include:</span></p>
<ul><li><ul>
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span> or <span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">ear infection</span></li>
<li>flu</li>
<li><span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span></li>
<li><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span></li>
</ul></li></ul>
<p><span class="Bold">Other side effects with montelukast sodium include:</span></p>
<ul><li><ul>
<li>increased <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">bleeding tendency</span>, low blood platelet count</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> [including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, and/or throat (which may cause trouble breathing or swallowing), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, pins and needles/<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> or fits)</li>
<li><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></li>
<li><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nose bleed</span>, stuffy nose</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, stomach or intestinal upset, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
</ul></li></ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of montelukast sodium. For more information ask your healthcare provider or pharmacist.</p>
<p>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store montelukast sodium?</span></p>
<ul>
<li>Store montelukast sodium at 20Â° to 25Â°C (68Â° to 77Â°F).</li>
<li>Keep montelukast sodium in the container it comes in.</li>
<li>Keep montelukast sodium in a dry place and away from light.</li>
</ul>
<p><span class="Bold">General Information about the safe and effective use of montelukast sodium</span></p>
<p>Medicines are sometimes prescribed for purposes other than those mentioned in Patient Information Leaflets. Do not use montelukast sodium for a condition for which it was not prescribed. Do not give montelukast sodium to other people even if they have the same symptoms you have. It may harm them. <span class="Bold">Keep montelukast sodium and all medicines out of the reach of children.</span></p>
<p>This leaflet summarizes information about montelukast sodium. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about montelukast sodium that is written for health professionals. For more information, call 1-888-838-2872, MEDICAL AFFAIRS.</p>
<p><span class="Bold">What are the ingredients in montelukast sodium tablets and chewable tablets?</span></p>
<p><span class="Bold">Active ingredient:</span> montelukast sodium</p>
<p><span class="Bold">Inactive ingredients:</span></p>
<ul>
<li>10 mg tablet: hydroxypropyl cellulose, hypromellose, iron oxide red, iron oxide yellow, lactose monohydrate (128.6 mg), magnesium stearate, pregelatinized starch, sodium lauryl sulfate, sodium starch glycolate, and titanium dioxide.</li>
<li>4 mg and 5 mg chewable tablets: aspartame, cherry flavoring [which contains maltodextrins (maize) and starch modified (waxy maize)], ferric oxide red, hydroxypropyl cellulose, magnesium stearate, mannitol granulate, sodium lauryl sulfate, and sodium starch glycolate.</li>
</ul>
<p>People with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span>: Montelukast sodium chewable tablets, 4 mg (montelukast) contain 0.28 mg of phenylalanine, and montelukast sodium chewable tablets, 5 mg (montelukast) contain 0.28 mg of phenylalanine.</p>
<p><span class="Italics">Pediatric use information for patients ages 6 to 14 years  of age for prevention of  exercise-induced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> is approved for Merck Sharp &amp; Dohme Corpâ€™s montelukast tablet products. However, due to Merck Sharp &amp; Dohme Corpâ€™s marketing exclusivity rights, this drug product is  not labeled with that pediatric information.</span></p>
<p>Manufactured In Israel By:</p>
<p><span class="Bold">TEVA PHARMACEUTICAL IND. LTD.</span></p>
<p>Jerusalem, 91010, Israel</p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Rev. A 7/2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_15898d33-9bf0-4ec8-8fe7-a44f5416f337"></a><a name="section-17"></a><p></p>
<h1>Principal Display Panel</h1>
<div class="Figure"><img alt="Montelukast Sodium Tablets 10 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=09692f56-468c-4884-ae95-d2fb9d984e4c&amp;name=6361.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_edfac567-8a34-47eb-9d84-99d9bb5d7580"></a><a name="section-17.1"></a><p></p>
<h2>Montelukast Sodium Tablets 10 mg Label Text</h2>
<p class="First"><span class="Bold"></span><br></p>
<p><span class="Bold">MONTELUKAST<br>SODIUM Tablets</span></p>
<p><span class="Bold">For Patients 15 Years of Age<br>and Older</span></p>
<p><span class="Bold">10 mg*</span></p>
<p><span class="Bold">Rx only</span></p>
<p>PHARMACIST: PLEASE DISPENSE WITH<br>ATTACHED PATIENT INFORMATION LEAFLET</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_5ee6003d-e0fa-4639-bf9f-ddaa6e987a10"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Montelukast Sodium Chewable Tablets 4 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=09692f56-468c-4884-ae95-d2fb9d984e4c&amp;name=6363.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_01e12edc-4ad4-409c-967b-a39b80c15dce"></a><a name="section-18.1"></a><p></p>
<h2>Montelukast Sodium Chewable Tablets 4 mg Label Text</h2>
<p class="First"><span class="Bold"></span><br></p>
<p><span class="Bold">MONTELUKAST SODIUM<br>Chewable Tablets, 4 mg*</span></p>
<p><span class="Bold">For Pediatric Patients<br>2 to 5 Years of Age</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Italics">Phenylketonurics:</span> contains phenylalanine<br>(a component of aspartame) 0.28 mg per<br>4 mg chewable tablet.</p>
<p>PHARMACIST: PLEASE DISPENSE WITH<br>ATTACHED PATIENT INFORMATION LEAFLET</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_4f0e05c6-416b-438e-af17-d60ace0466c5"></a><a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Montelukast Sodium Chewable Tablets 5 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=09692f56-468c-4884-ae95-d2fb9d984e4c&amp;name=6362.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bc2051a5-b58c-406c-92a6-df8dac942f78"></a><a name="section-19.1"></a><p></p>
<h2>Montelukast Sodium Chewable Tablets 5 mg Label Text</h2>
<p class="First"><span class="Bold"></span><br></p>
<p><span class="Bold">MONTELUKAST SODIUM<br>Chewable Tablets, 5 mg*</span></p>
<p><span class="Bold">For Pediatric Patients<br>6 to 14 Years of Age</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Italics">Phenylketonurics:</span> contains phenylalanine<br>(a component of aspartame) 0.28 mg per<br>5 mg chewable tablet.</p>
<p>PHARMACIST: PLEASE DISPENSE WITH<br>ATTACHED PATIENT INFORMATION LEAFLET</p>
<br>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MONTELUKAST SODIUMÂ 		
					</strong><br><span class="contentTableReg">montelukast sodium tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6361(NDC:0093-7426)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MONTELUKAST SODIUM</strong> (MONTELUKAST) </td>
<td class="formItem">MONTELUKAST</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (beige) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TV;7426</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6361-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-6361-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078605</td>
<td class="formItem">08/09/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MONTELUKAST SODIUMÂ 		
					</strong><br><span class="contentTableReg">montelukast sodium tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6363(NDC:0093-7424)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MONTELUKAST SODIUM</strong> (MONTELUKAST) </td>
<td class="formItem">MONTELUKAST</td>
<td class="formItem">4Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (mottled pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TRIANGLE (arc triangle shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TV;7424</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6363-0</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-6363-1</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078723</td>
<td class="formItem">08/09/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MONTELUKAST SODIUMÂ 		
					</strong><br><span class="contentTableReg">montelukast sodium tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6362(NDC:0093-7425)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MONTELUKAST SODIUM</strong> (MONTELUKAST) </td>
<td class="formItem">MONTELUKAST</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (mottled pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">SQUARE</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TV;7425</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6362-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078723</td>
<td class="formItem">08/09/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-6361, 54868-6363, 54868-6362), repack(54868-6361, 54868-6363, 54868-6362)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1006e476-bae4-4924-bb59-9f8a5bfaba73</div>
<div>Set id: 09692f56-468c-4884-ae95-d2fb9d984e4c</div>
<div>Version: 2</div>
<div>Effective Time: 20120914</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
